Research programme: nerve growth factor inhibitors - Amgen
Latest Information Update: 09 Sep 2008
At a glance
- Originator Amgen
- Class Monoclonal antibodies; Peptides
- Mechanism of Action Nerve growth factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 29 Mar 2004 Preclinical trials in Pain in USA (unspecified route)